Kirby McInerney LLP is investigating Qiagen N.V. for potential violations of federal securities laws following the company's disclosure of a sales decline. Qiagen had previously forecasted 6-7% growth for its QuantiFERON product in 2026, but later reported a 1% overall sales decline and a 5% drop in QuantiFERON sales for Q1 2026. This news caused an 11% drop in Qiagen's stock price. The investigation is ongoing, and no lawsuit has been filed yet. Investors who purchased Qiagen securities are encouraged to contact the law firm for more information or to discuss their rights.
Hexagon AB has distributed all shares of its subsidiary Octave Intelligence plc to its shareholders, making Octave an independent public company. Octave's shares began trading on Nasdaq Stockholm under the ticker OCTV SDB and will start trading on Na...
Hexagon AB has distributed all shares of its subsidiary Octave Intelligence plc to its shareholders, with Octave's shares now trading on Nasdaq Stockholm under the ticker OCTV SDB and on Nasdaq New York under OCTV. Shareholders received Octave shares...
J.P. Morgan Asset Management announced the final cash distributions for May 2026 for two of its ETFs listed on the Toronto Stock Exchange: the JPMorgan Active U.S. Equity Premium Income ETF (JEPI) will pay $0.16424 per share, and the JPMorgan Active ...
Coda Octopus Group, a leader in advanced underwater imaging sonar and diving technology, announced it will hold its Fiscal Second Quarter 2026 earnings conference call on June 15, 2026. The company will release its financial results before the market...
The global coffee substitute market, valued at $15.5 billion in 2025, is projected to grow at a 4.8% CAGR to reach $24.3 billion by 2035. Growth is fueled by rising consumer awareness of caffeine-related health issues and a shift towards clean-label,...
